Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-021-04377-0 ◽

2021 ◽

Author(s):

Stefanie D. Krens ◽

Sasja F. Mulder ◽

Nielka P. van Erp

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Third Space ◽

Malignant Ascites

Download Full-text

Dasatinib (BMS-354825), a dual SRC/ABL tyrosine kinase inhibitor, inhibits tumor formation and prevents malignant ascites in a murine model of peritoneal carcinomatosis

Journal of the American College of Surgeons ◽

10.1016/j.jamcollsurg.2006.05.229 ◽

2006 ◽

Vol 203 (3) ◽

pp. S87-S88 ◽

Cited By ~ 1

Author(s):

Donald Lesslie ◽

Nila Parikh ◽

Ami Shah ◽

Justin Summy ◽

Jose Trevino ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Peritoneal Carcinomatosis ◽

Murine Model ◽

Kinase Inhibitor ◽

Malignant Ascites ◽

Tumor Formation ◽

Abl Tyrosine Kinase ◽

Abl Tyrosine Kinase Inhibitor

Download Full-text

Both Antiangiogenesis- and Angiogenesis-Independent Effects Are Responsible for Hepatocellular Carcinoma Growth Arrest by Tyrosine kinase Inhibitor PTK787/ZK222584

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70211-2 ◽

2006 ◽

Vol 2006 ◽

pp. 309-310

Author(s):

P.J. Loehrer

Keyword(s):

Hepatocellular Carcinoma ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Growth Arrest ◽

Independent Effects

Download Full-text

Dual-agent molecular targeting of growth factor receptors in hepatocellular cancer: Combining anti-EGFR antibody with an EGFR tyrosine kinase inhibitor

Zeitschrift für Gastroenterologie ◽

10.1055/s-2005-920152 ◽

2005 ◽

Vol 43 (05) ◽

Author(s):

A Hüther ◽

M Höpfner ◽

D Schuppan ◽

H Scherübl

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Hepatocellular Cancer ◽

Growth Factor Receptors ◽

Molecular Targeting ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Egfr Antibody

Download Full-text

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

10.32388/jfobd7 ◽

2020 ◽

Author(s):

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Epidermal Growth

Download Full-text

A Case of Metastatic Renal Cell Carcinoma to the Maxillary Sinus Treated with Tyrosine Kinase Inhibitor

Korean Journal of Otorhinolaryngology - Head and Neck Surgery ◽

10.3342/kjorl-hns.2012.55.11.717 ◽

2012 ◽

Vol 55 (11) ◽

pp. 717 ◽

Cited By ~ 2

Author(s):

Young Hyo Kim ◽

Jae Eun Kim ◽

Sungmin Park ◽

Tae Young Jang

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cell Carcinoma ◽

Maxillary Sinus ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor

Download Full-text

Tyrosine kinase inhibitor (TKI) treatment outcome of stage IV-C thyroid differentiated cancer (analyzed by lesion evaluation)

Endocrine Abstracts ◽

10.1530/endoabs.56.p1139 ◽

2018 ◽

Author(s):

Hiroyuki Iwasaki ◽

Haruhiko Yamazaki ◽

Nobuyasu Suganuma ◽

Yuko Sugawara ◽

Naoki Gotoh ◽

...

Keyword(s):

Treatment Outcome ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Stage Iv ◽

Tki Treatment

Download Full-text

17 / An Observational Study of Survival in Patients With Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY)

10.26226/morressier.5b3b802cb1b87b000eced8f4 ◽

2018 ◽

Author(s):

Mauro Michael J.

Keyword(s):

Chronic Myeloid Leukemia ◽

Observational Study ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Chronic Phase

Download Full-text

08 / Caring for Patients With Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitor (TKI) Therapy in an Era of Evolving Treatment Goals

10.26226/morressier.5b3b802cb1b87b000eced8ee ◽

2018 ◽

Author(s):

Nodzon Lisa A.

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Treatment Goals

Download Full-text

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Egfr Tki

Download Full-text

Faculty Opinions recommendation of Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1061886.541558 ◽

2007 ◽

Author(s):

Karen Anderson

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Her Family ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text